BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 15375779)

  • 1. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
    Batista MC; Welty FK; Diffenderfer MR; Sarnak MJ; Schaefer EJ; Lamon-Fava S; Asztalos BF; Dolnikowski GG; Brousseau ME; Marsh JB
    Metabolism; 2004 Oct; 53(10):1255-61. PubMed ID: 15375779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
    Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
    J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men.
    Chan DC; Watts GF; Ng TW; Uchida Y; Sakai N; Yamashita S; Barrett PH
    Clin Biochem; 2005 Sep; 38(9):806-12. PubMed ID: 15992790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein metabolism in subjects with hepatic lipase deficiency.
    Tilly-Kiesi M; Schaefer EJ; Knudsen P; Welty FK; Dolnikowski GG; Taskinen MR; Lichtenstein AH
    Metabolism; 2004 Apr; 53(4):520-5. PubMed ID: 15045702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
    Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Nyaku M; Horvath KV; Asztalos BF; Otokozawa S; Ai M; Matthan NR; Lichtenstein AH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1672-8. PubMed ID: 18566298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2966-74. PubMed ID: 10591677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans.
    Welty FK; Lichtenstein AH; Barrett PH; Jenner JL; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1807-10. PubMed ID: 10894821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
    Matthan NR; Welty FK; Barrett PH; Harausz C; Dolnikowski GG; Parks JS; Eckel RH; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1092-7. PubMed ID: 15087307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.
    Elias N; Patterson BW; Schonfeld G
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1309-15. PubMed ID: 10807747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.
    Riches FM; Watts GF; Naoumova RP; Kelly JM; Croft KD; Thompson GR
    Int J Obes Relat Metab Disord; 1998 May; 22(5):414-23. PubMed ID: 9622338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
    Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH
    Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
    Millar JS; Duffy D; Gadi R; Bloedon LT; Dunbar RL; Wolfe ML; Movva R; Shah A; Fuki IV; McCoy M; Harris CJ; Wang MD; Howey DC; Rader DJ
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):140-6. PubMed ID: 18988892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.